ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 0842 • ACR Convergence 2024

    The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository (“Registry”)

    Reyhan Kose Cobanoglu1, Rohan Willis2, Diana Paredes-Ruiz3, Maria G Tektonidou4, Vittorio Pengo5, Savino Sciascia6, Cecilia Nalli7, Flavio Victor Signorelli8, Paul Fortin9, Maria Efthymiou10, H Michael Belmont11, Michelle Petri12, Ricard Cervera13, Megan Barber14, TATSUYA ATSUMI15, Chary Lopez-Pedrera16, Jason Knight17, David Branch18, Nina Kello19, Lanlan Ji20, Esther Rodriguez-Almaraz21, Bahar Artim Esen22, Jose Pardos Gea23, Rosana Quintana24, Giulia Pazzola25, Hui Shi26, Ali Duarte-Garcia27, Pierluigi Meroni28, Robert Roubey29, Maria Laura Bertolaccini30, Hannah Cohen31, Danieli Andrade32 and Doruk Erkan33, and on behalf of APS ACTION, 1Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 2University of Texas Medical Branch, Galveston, TX, 3Biocruces Bizkaia Health Research Institute, Bizkaia, Spain, 4National and Kapodistrian University of Athens, Athens, Greece, 5Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 6University of Turin, Torino, Turin, Italy, 7ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 8Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 9Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 10University College London, London, United Kingdom, 11NYU School of Medicine, New York, NY, 12Johns Hopkins University School of Medicine, Timonium, MD, 13Hospital Clinic de Barcelona, Barcelona, Spain, 14Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 15Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 16IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 17University of Michigan, Ann Arbor, MI, 18University of Utah and Intermountain Healthcare, Salt Lake City, UT, 19Northwell Health, Brooklyn, NY, 20Peking University First Hospital, Peking, China (People's Republic), 21Hospital Universitario 12 de Octubre, Madrid, Spain, 22Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 23Vall d'Hebron University Hospital, Barcelona, Spain, 24Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 25Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, 26Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), 27Mayo Clinic, Rochester, MN, 28IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 29Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 30King's College London, London, United Kingdom, 31University College London Hospitals NHS Foundation Trust, London, United Kingdom, 32University of São Paulo, São Paulo, SP, Brazil, 33Hospital for Special Surgery, New York, NY

    Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases…
  • Abstract Number: 0929 • ACR Convergence 2024

    UVB-Induced Keratinocyte-Derived Extracellular Vesicles: Cytokeratin 10 as a Marker of Epidermal Origin

    Ahmed Eldaboush1, Cristina Ricco1, Luca Musante1, Rohan Dhiman2, Avital Baniel3, Daniella Faden1, Caroline Stone1, Ming-Lin Liu1 and Victoria Werth4, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Newport Coast, CA, 3Perelman School of Medicine, UPENN, Philadelphia, PA, 4University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Extracellular vesicles (EVs) are small lipid-bilayer particles released from cells that mediate various functions through their cargo, which includes proteins and nucleic acids. EVs…
  • Abstract Number: 1008 • ACR Convergence 2024

    Immune Responses to Infection and Autoimmune Diseases in the UK Biobank

    Choa Yun1, May A. Beydoun2, Lenore Launer2 and Minkyo Song3, 1National Institute on Aging, Rockville, MD, 2National Institute on Aging, Baltimore, MD, 3National Institutes on Aging, Baltimore, MD

    Background/Purpose: Infections have been implicated as potential triggers for autoimmune responses, but studies primarily focused on the history of infection linked with autoimmune diseases. Large-scale…
  • Abstract Number: 1225 • ACR Convergence 2024

    Fibromyalgia as a Potential Initial Presentation for Autoimmune Conditions

    Qi Wang1, Pratibha Chaudhary2, Yu Chang3 and Megha Garg4, 1Unity Hospital/Rochester Regional Health, Rochester, NY, 2Rochester General Hospital, Rochester, NY, 3National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), 4Rochester Regional Health, Rochester, NY

    Background/Purpose: Fibromyalgia is a non-autoimmune disease with widespread pain, severe fatigue, and sleep problems. There are limited studies examining the association between fibromyalgia and autoimmune…
  • Abstract Number: 1488 • ACR Convergence 2024

    Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays

    Mariana Gonzalez-Trevino1, MeLea Hetrick1, Alain Sanchez-Rodriguez2, Ali Duarte-Garcia1 and Anne Tebo3, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic College of Medicine and Science, Rochester, MN, 3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

    Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…
  • Abstract Number: 1650 • ACR Convergence 2024

    IL-33 Expands Plasma Cells, Disrupts Germinal Centers and Increases Autoantibody Production

    Andre Limnander1, Eva Conde1, Seblewongel Asrat2, Andrea Vecchione2, Kaitlyn Gayvert2, Paulina Pedraza2, Carley Tasker2, Sharon Huang2, Dmitry Yarilin2, Dylan Birchard2, Li-Hong Ben2, Wei Keat Lim2, Andrew Murphy2, Matthew Sleeman2 and Jamie orengo1, 1Regeneron Pharmaceuticals, Tarrytown, NY, 2Regeneron Pharmaceuticals, Tarrytown

    Background/Purpose: IL-33 is a pro-inflammatory cytokine that plays a role in asthma, COPD and autoimmune diseases. The role of IL-33 on B cell maturation and…
  • Abstract Number: 1764 • ACR Convergence 2024

    Reduction in Circulating Neutrophil Extracellular Traps and Restored Degradation Post-treatment in Pediatric Lupus

    Tatiana Borja1, Bharati Matta2, Lydia Thomas3, Jenna Battaglia4, Amanda Huang5, Kim Simpfendorfer6, Hongxiu Wen5, Joyce Hui-Yuen7, Boris Reizis8, Sohei Makita8 and Betsy Barnes5, 1Northwell- Cohen Children's Medical Center, Elmhurst, NY, 2The Feinstein Institutes for Medical Research, Manhasset, NY, 3Northwell Health - Cohen Children's Medical Center, Lake Success, NY, 4Feinstein Institutes for Medical Science, Manhasset, 5Feinstein Institutes for Medical Science, Manhasset, NY, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Northwell Health, Cohen Children's Medical Center, Great Neck, NY, 8New York University Grossman School of Medicine, New York, NY

    Background/Purpose: Pediatric lupus (pSLE) is a multisystemic, chronic, autoimmune disease in which over 50% of pSLE patients develop lupus nephritis (pLN). Neutrophil extracellular traps (NETs)…
  • Abstract Number: 1842 • ACR Convergence 2024

    Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy

    John Goulding1, John Reiser2, Alison O'Connor1, Bryan Hancock1, Jonatan Tuncel1, Brian Groff1, Rina Mbofung1, Daniel Morales-Mantilla1, Allan Williams1, Dan Lu1, Bi-Huei Yang1, Eigen Peralta1, Alma Gutierrez1, Miguel Meza1, Betsy Rezner1, Amanda Sims1, Alec Witty1, Yijia Pan1, Mark Jelcic1, Shohreh Sikaroodi1, Matthew Denholtz1, Tom Lee1, Anil Bagri1, Lilly Wong1, Jode Goodridge1 and Bahram Valamehr1, 1Fate Therapeutics Inc., San Diego, CA, 2Fate Therapeutics Inc, San Diego, CA

    Background/Purpose: Developed initially as a novel strategy to treat B cell malignancies, chimeric antigen receptor (CAR) T cells have now been used to treat multiple…
  • Abstract Number: 1979 • ACR Convergence 2024

    Safety and Effectiveness of Immune Checkpoint Inhibitor Therapy in Patients with Pre-existing Autoimmune Disease

    Siddhartha Goutam1, Arjun athreya Raghavan2, Carrie Ye3, Liam O'Neil4 and Jeffrey Graham1, 1Max Rady School of Medicine, University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba Max Rady College of Medicine, Winnipeg, MB, Canada, 3Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 4University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Immune checkpoint inhibitors (ICI) have altered the treatment landscape within oncology, with an expanding number of indications. Patients with pre-existing autoimmune disease (PAD) have…
  • Abstract Number: 2079 • ACR Convergence 2024

    Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study

    Silvia Grazzini1, Angeles Galindo-Feria2, Edoardo Conticini1, Ingrid Lundberg3 and Maryam Dastmalchi4, 1Università di Siena, Siena, Italy, 2Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 3Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 4Karolinska University hospital, Stockholm, Sweden

    Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is a recently recognized subtype of idiopathic inflammatory myopathy (IIM). This condition is marked by the sudden onset of…
  • Abstract Number: 2404 • ACR Convergence 2024

    Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus

    Caroline Stone1, Daniella Faden1, Lillian Xie1, Lais Lopes Almeida Gomes1, Joshua Dan1, Cristina Ricco1, Ahmed Eldaboush1 and Victoria Werth2, 1University of Pennsylvania, philadelphia, PA, 2University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Dermatoscopes are emerging as efficient, valuable alternatives to capillaroscopy for evaluating rheumatologic conditions. Second to systemic sclerosis, nailfold capillaroscopy abnormalities are most consistently reported…
  • Abstract Number: 2538 • ACR Convergence 2024

    HLA-DRB1 Rheumatoid Arthritis (RA) Risk Alleles Preferentially Select TRBJ2-3-containing CD4 T Cells in RA Patients

    Amit Lakhanpal1, Kazuyoshi Ishigaki2, Anvita Singaraju1, Alejandro Kochen3, Miriam Fein1, Soumya Raychaudhuri4 and Laura Donlin1, 1Hospital for Special Surgery, New York, NY, 2Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan; Keio University Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q);; Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Bunkyo-ku, Tokyo, Japan, 3Yale School of Medicine, New Haven, CT, 4Brigham and Women's Hospital, Boston, MA

    Background/Purpose: The largest genetic risk factor for RA localizes to the MHC Class II HLA-DRB1 gene, which encodes the machinery for antigen presentation to CD4…
  • Abstract Number: 2663 • ACR Convergence 2024

    ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications

    Monica Moreno, Shon Green, Kevin P. Nishimoto, Jackie Kennedy-Wilde, Taylor Barca, Melinda Au, Simona Costanzo, Gregory Vosganian, Benjamin Hsu, Francesco Galimi and Blake T. Aftab, Adicet Therapeutics, Inc., Redwood City, CA

    Background/Purpose: γδ T cells serve a role in immune surveillance and their capability to traffic to tissues is fundamental to their natural biology1. They are…
  • Abstract Number: 0008 • ACR Convergence 2024

    Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease

    Ashley Mahne1, Ryan Rodriguez2, Jessica Wang1, Daniel Anaya1, Joseph K. Cheng1, Brandon Kwong1, Jesus Banuelos3, Peter Starokadomskyy3, Soo Park3, Candice Gibson4, Shouvonik Sengupta1, Simone Sandoval1, Jazmin Bravo3, Jeanne Flandez1, Shairaz Shah1, Amanda Goodsell1, Nicole Khoshnoodi1, Jennifer Zeng1, Santiago Foos-Russ1, Mario Lorente1, Jennifer Adrian1, Timothy Klasson1, Yong Zhang5, Jessica Seitzer6, Birgit Schultes5 and Tom Van Blarcom3, 1Kyverna Therapeutics, Inc., Emeryville, CA, 2Kyverna Therapeutics, Inc., Emerville, CA, 3Kyverna Therapeutics, Inc., Emeryville, 4Kyverna Therapeutics, Inc., Emerybille, 5Intellia Therapeutics, Inc., Cambridge, MA, 6Intellia Therapeutics, Inc., Cambridge

    Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
  • Abstract Number: 0093 • ACR Convergence 2024

    Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure

    Benjamin Klein1, Kelsey E. McNeely2, Debbie Colesa2, Yiqing Gao2, Nguyen Thi Kim Nguyen2, Johann Gudjonsson1 and J. Michelle Kahlenberg1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Skin involvement is the most common organ manifestation in systemic lupus erythematosus (SLE), and exacerbation of cutaneous lupus (CLE) can precede systemic disease flares.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology